CyFlow™ CD106 Biotin
Alternative Name: | INCAM-110, VCAM-1 |
Antibody: | Yes |
Antigen: | CD106 |
Application: | Flow cytometry |
Clonality: | monoclonal |
Clone: | STA |
Field of Interest: | Immunophenotyping |
Format/Fluorochrome: | Biotin |
Isotype: | IgG1 |
Regulatory Status: | RUO |
Source Species: | Mouse |
Target Species: | Human |
Product number: | CX097139 |
For Research Use Only
HLDA Workshop | HLDA V—WS Code A013 |
Concentration Unit | mg/mL |
Concentration | 1 |
Quantity | 0.1 mg |
Volume | 0.1 mL |
Immunogen | Human DS6 T cells |
Background Information | CD106 (VCAM-1; vascular cell adhesion molecule-1) is an Ig-like cell surface adhesion molecule binding VLA-4 integrin. VCAM-1 is a potent T cell costimulatory molecule taking part in their positive selection and survival, as well as in adhesion, transendothelial migration and activation of peripheral T cells. VCAM-1 is also involved in endothelial cell-cell contacts. Whereas VCAM-1 normally mediates leukocyte extravasion to sites of tissue inflammation, tumor cells can use overexpressed VCAM-1 to escape T cell immunity. Soluble form of VCAM-1 (sVCAM-1) is an inflammatory marker and can be used also in prognosis of subsequent cariovascular events following acute coronary syndromes. |
Usage | The reagent is designed for indirect immunofluorescence analysis by Flow Cytometry. Suggested working usage is 8·µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator. |
Storage Buffer | The reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
Stability | Do not use after expiration date stamped on vial label. |
| Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non‑macrophage derived tumours in cytological specimens. J Clin Pathol. 1993 Apr; 46(4):334‑6. < PMID: 7684403 > | Leca G, Mansur SE, Bensussan A: Expression of VCAM‑1 (CD106) by a subset of TCR gamma delta‑bearing lymphocyte clones: Involvement of a metalloprotease in the specific hydrolytic release of the soluble isoform. J Immunol. 1995 Feb 1; 154(3):1069‑77. < PMID: 7529789 > | van Wetering S, van den Berk N, van Buul JD, Mul FP, Lommerse I, Mous R, ten Klooster JP, Zwaginga JJ, Hordijk PL: VCAM‑1‑mediated Rac signaling controls endothelial cell‑cell contacts and leukocyte transmigration. Am J Physiol Cell Physiol. 2003 Aug; 285(2):C343‑52. < PMID: 12700137 > | Yen YT, Liao F, Hsiao CH, Kao CL, Chen YC, Wu-Hsieh BA: Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol. 2006 Mar; 80(6):2684‑93. < PMID: 16501078 > | Wu TC: The role of vascular cell adhesion molecule‑1 in tumor immune evasion. Cancer Res. 2007 Jul 1; 67(13):6003‑6. < PMID: 17616653 > | Postadzhiyan AS, Tzontcheva AV, Kehayov I, Finkov B: Circulating soluble adhesion molecules ICAM‑1 and VCAM‑1 and their association with clinical outcome, troponin T and C‑reactive protein in patients with acute coronary syndromes. Clin Biochem. 2007 Sep 19; < PMID: 23105687 > | Paessens LC, Singh SK, Fernandes RJ, van Kooyk Y: Vascular cell adhesion molecule‑1 (VCAM‑1 and intercellular adhesion molecule‑1 (ICAM‑1 provide co‑stimulation in positive selection along with survival of selected thymocytes. Mol Immunol. 2008 Jan; 45(1):42‑8. < PMID: 17604837 >